文献速递淋巴瘤

慢性淋巴细胞白血病:仅由两种生物标志物(IGHV 突变状态和 FISH 细胞遗传学)组成的预后模型可区分不同结局患者并简化 CLL-IPI

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
PubMed 文献 · Am J Hematol · 2017-02-13

该研究基于 IGHV 突变状态和 FISH 细胞遗传学两种生物标志物构建仅含生物标志物的 CLL 预后系统,将患者分为低危、中危和高危三组;在 524 例未选择 CLL 患者中,三组 10 年总生存率分别为 82%、52% 和 27%,并在两个独立队列中完成验证,判别价值与 CLL-IPI 相似。

要点

  • 低危组(IGHV 突变且无不良 FISH)约占系列 50%,预期寿命与一般人群相当。
  • 中危组(IGHV 未突变或不良 FISH)和高危组(IGHV 未突变且不良 FISH)10 年总生存率分别为 52% 和 27%。
  • 该模型在包括 417 例一般 CLL 人群代表和 337 例 Binet A 期患者的两个独立队列中获完全验证。

核心结论

  • 仅基于 IGHV 突变状态和 FISH 细胞遗传学的 CLL 预后系统可区分三个不同风险组,判别价值与 CLL-IPI 相似,可简化 CLL-IPI,可能有助于日常实践和临床试验中的患者分层。

研究设计与样本

  • 研究纳入 524 例未选择的 CLL 患者,基于 IGHV 突变状态和 FISH 细胞遗传学构建仅含生物标志物的预后系统,并在两个独立队列(417 例代表一般 CLL 人群和 337 例 Binet A 期 CLL 患者)中完全验证。

主要发现

  • 在 524 例未选择 CLL 患者中,低危、中危和高危组的 10 年总生存率分别为 82%(95% CI 76%-88%)、52%(45%-62%)和 27%(17%-42%)。
  • 低危组约占系列的 50%,其预期寿命与一般人群相当。
  • 该模型在包括 417 例一般 CLL 人群代表和 337 例 Binet A 期 CLL 患者的两个独立队列中获完全验证。
  • 该模型的判别价值与 CLL-IPI 相似,且适用于所有 CLL 患者而不论年龄,并可在 Rai 或 Binet 临床分期内部区分不同风险患者。

关键数值与推荐

  • 低危:IGHV 突变且无不良 FISH 细胞遗传学(del(17p)、del(11q))。
  • 中危:IGHV 未突变或不良 FISH 细胞遗传学。
  • 高危:IGHV 未突变且不良 FISH 细胞遗传学。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rai and Binet staging systems are important to predict the outcome of patients with chronic lymphocytic leukemia (CLL) but do not reflect the biologic diversity of the disease nor predict response to therapy, which ultimately shape patients' outcome. We devised a biomarkers-only CLL prognostic system based on the two most important prognostic parameters in CLL (i.e., IGHV mutational status and fluorescence in situ hybridization [FISH] cytogenetics), separating three different risk groups: (1) low-risk (mutated IGHV + no adverse FISH cytogenetics [del(17p), del(11q)]); (2) intermediate-risk (either unmutated IGHV or adverse FISH cytogenetics) and (3) high-risk (unmutated IGHV + adverse FISH cytogenetics). In 524 unselected subjects with CLL, the 10-year overall survival was 82% (95% CI 76%-88%), 52% (45%-62%), and 27% (17%-42%) for the low-, intermediate-, and high-risk groups, respectively. Patients with low-risk comprised around 50% of the series and had a life expectancy comparable to the general population. The prognostic model was fully validated in two independent cohorts, including 417 patients representative of general CLL population and 337 patients with Binet stage A CLL. The model had a similar discriminatory value as the CLL-IPI. Moreover, it applied to all patients with CLL independently of age, and separated patients with different risk within Rai or Binet clinical stages. The biomarkers-only CLL prognostic system presented here simplifies the CLL-IPI and could be useful in daily practice and to stratify patients in clinical trials.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Delgado J, Doubek M, Baumann T, et al. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol. 2017. PMID: 28120419. doi:10.1002/ajh.24660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。